img

Global Therapeutic HIV Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Therapeutic HIV Vaccine Market Insights, Forecast to 2034

A therapeutic HIV vaccine is a vaccine that is designed to improve the body's immune response to HIV in a person who already has HIV.
Global Therapeutic HIV Vaccine market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Therapeutic HIV Vaccine industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
According to the United Nations AIDS Program (UNAIDS), 38.4 million people are currently infected with HIV worldwide, and 1.5 million people will be newly infected in 2021. HIV has always been a difficult problem facing the world. After years of research and trials, except for a very few cases of bone marrow transplantation, there is currently no cure for this infection. It can only be controlled indefinitely with antiviral drugs. Prevents it from developing into the fatal immunodeficiency syndrome (AIDS). The main reason for the difficulty in developing an AIDS vaccine is the genetic diversity and mutation ability of the HIV virus, which enables it to effectively escape the human immune system. In addition, the conformation of the antigenic protein Env on the surface of the HIV virus is very unstable before fusion, which is a difficult problem that scientists have faced for many years.
Report Covers
This report presents an overview of global Therapeutic HIV Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Therapeutic HIV Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


ViiV Healthcare
Mylan
AbbVie
Merck & Co., Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Genentech, Inc.
Cipla, Inc.
Segment by Type
NRTIs
NNRTIs
Entry and Fusion Inhibitors
Protease Inhibitors
Integrase Inhibitors
Coreceptor Antagonists

Segment by Application


Hospitals
Clinics
Labs

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Therapeutic HIV Vaccine plant distribution, commercial date of Therapeutic HIV Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Therapeutic HIV Vaccine introduction, etc. Therapeutic HIV Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Therapeutic HIV Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Therapeutic HIV Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Therapeutic HIV Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 NRTIs
1.2.3 NNRTIs
1.2.4 Entry and Fusion Inhibitors
1.2.5 Protease Inhibitors
1.2.6 Integrase Inhibitors
1.2.7 Coreceptor Antagonists
1.3 Market by Application
1.3.1 Global Therapeutic HIV Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Therapeutic HIV Vaccine Sales Estimates and Forecasts 2018-2029
2.2 Global Therapeutic HIV Vaccine Revenue by Region
2.2.1 Global Therapeutic HIV Vaccine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Therapeutic HIV Vaccine Revenue by Region (2018-2024)
2.2.3 Global Therapeutic HIV Vaccine Revenue by Region (2024-2029)
2.2.4 Global Therapeutic HIV Vaccine Revenue Market Share by Region (2018-2029)
2.3 Global Therapeutic HIV Vaccine Sales Estimates and Forecasts 2018-2029
2.4 Global Therapeutic HIV Vaccine Sales by Region
2.4.1 Global Therapeutic HIV Vaccine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Therapeutic HIV Vaccine Sales by Region (2018-2024)
2.4.3 Global Therapeutic HIV Vaccine Sales by Region (2024-2029)
2.4.4 Global Therapeutic HIV Vaccine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Therapeutic HIV Vaccine Sales by Manufacturers
3.1.1 Global Therapeutic HIV Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Therapeutic HIV Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Therapeutic HIV Vaccine in 2022
3.2 Global Therapeutic HIV Vaccine Revenue by Manufacturers
3.2.1 Global Therapeutic HIV Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Therapeutic HIV Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Therapeutic HIV Vaccine Revenue in 2022
3.3 Global Key Players of Therapeutic HIV Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Therapeutic HIV Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Therapeutic HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Therapeutic HIV Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Therapeutic HIV Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Therapeutic HIV Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Therapeutic HIV Vaccine Sales by Type
4.1.1 Global Therapeutic HIV Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Therapeutic HIV Vaccine Forecasted Sales by Type (2024-2029)
4.1.3 Global Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Therapeutic HIV Vaccine Revenue by Type
4.2.1 Global Therapeutic HIV Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Therapeutic HIV Vaccine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Therapeutic HIV Vaccine Price by Type
4.3.1 Global Therapeutic HIV Vaccine Price by Type (2018-2024)
4.3.2 Global Therapeutic HIV Vaccine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Therapeutic HIV Vaccine Sales by Application
5.1.1 Global Therapeutic HIV Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Therapeutic HIV Vaccine Forecasted Sales by Application (2024-2029)
5.1.3 Global Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Therapeutic HIV Vaccine Revenue by Application
5.2.1 Global Therapeutic HIV Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Therapeutic HIV Vaccine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Therapeutic HIV Vaccine Price by Application
5.3.1 Global Therapeutic HIV Vaccine Price by Application (2018-2024)
5.3.2 Global Therapeutic HIV Vaccine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Therapeutic HIV Vaccine Market Size by Type
6.1.1 US & Canada Therapeutic HIV Vaccine Sales by Type (2018-2029)
6.1.2 US & Canada Therapeutic HIV Vaccine Revenue by Type (2018-2029)
6.2 US & Canada Therapeutic HIV Vaccine Market Size by Application
6.2.1 US & Canada Therapeutic HIV Vaccine Sales by Application (2018-2029)
6.2.2 US & Canada Therapeutic HIV Vaccine Revenue by Application (2018-2029)
6.3 US & Canada Therapeutic HIV Vaccine Market Size by Country
6.3.1 US & Canada Therapeutic HIV Vaccine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Therapeutic HIV Vaccine Sales by Country (2018-2029)
6.3.3 US & Canada Therapeutic HIV Vaccine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Therapeutic HIV Vaccine Market Size by Type
7.1.1 Europe Therapeutic HIV Vaccine Sales by Type (2018-2029)
7.1.2 Europe Therapeutic HIV Vaccine Revenue by Type (2018-2029)
7.2 Europe Therapeutic HIV Vaccine Market Size by Application
7.2.1 Europe Therapeutic HIV Vaccine Sales by Application (2018-2029)
7.2.2 Europe Therapeutic HIV Vaccine Revenue by Application (2018-2029)
7.3 Europe Therapeutic HIV Vaccine Market Size by Country
7.3.1 Europe Therapeutic HIV Vaccine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Therapeutic HIV Vaccine Sales by Country (2018-2029)
7.3.3 Europe Therapeutic HIV Vaccine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Therapeutic HIV Vaccine Market Size
8.1.1 China Therapeutic HIV Vaccine Sales (2018-2029)
8.1.2 China Therapeutic HIV Vaccine Revenue (2018-2029)
8.2 China Therapeutic HIV Vaccine Market Size by Application
8.2.1 China Therapeutic HIV Vaccine Sales by Application (2018-2029)
8.2.2 China Therapeutic HIV Vaccine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Therapeutic HIV Vaccine Market Size by Type
9.1.1 Asia Therapeutic HIV Vaccine Sales by Type (2018-2029)
9.1.2 Asia Therapeutic HIV Vaccine Revenue by Type (2018-2029)
9.2 Asia Therapeutic HIV Vaccine Market Size by Application
9.2.1 Asia Therapeutic HIV Vaccine Sales by Application (2018-2029)
9.2.2 Asia Therapeutic HIV Vaccine Revenue by Application (2018-2029)
9.3 Asia Therapeutic HIV Vaccine Sales by Region
9.3.1 Asia Therapeutic HIV Vaccine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Therapeutic HIV Vaccine Revenue by Region (2018-2029)
9.3.3 Asia Therapeutic HIV Vaccine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Therapeutic HIV Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Therapeutic HIV Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Information
11.1.2 ViiV Healthcare Overview
11.1.3 ViiV Healthcare Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 ViiV Healthcare Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ViiV Healthcare Recent Developments
11.2 Mylan
11.2.1 Mylan Company Information
11.2.2 Mylan Overview
11.2.3 Mylan Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Mylan Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Mylan Recent Developments
11.3 AbbVie
11.3.1 AbbVie Company Information
11.3.2 AbbVie Overview
11.3.3 AbbVie Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 AbbVie Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AbbVie Recent Developments
11.4 Merck & Co., Inc.
11.4.1 Merck & Co., Inc. Company Information
11.4.2 Merck & Co., Inc. Overview
11.4.3 Merck & Co., Inc. Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Merck & Co., Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck & Co., Inc. Recent Developments
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Information
11.5.2 Bristol-Myers Squibb Company Overview
11.5.3 Bristol-Myers Squibb Company Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Bristol-Myers Squibb Company Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bristol-Myers Squibb Company Recent Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Company Information
11.6.2 Boehringer Ingelheim GmbH Overview
11.6.3 Boehringer Ingelheim GmbH Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Boehringer Ingelheim GmbH Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boehringer Ingelheim GmbH Recent Developments
11.7 Genentech, Inc.
11.7.1 Genentech, Inc. Company Information
11.7.2 Genentech, Inc. Overview
11.7.3 Genentech, Inc. Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Genentech, Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Genentech, Inc. Recent Developments
11.8 Cipla, Inc.
11.8.1 Cipla, Inc. Company Information
11.8.2 Cipla, Inc. Overview
11.8.3 Cipla, Inc. Therapeutic HIV Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Cipla, Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cipla, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Therapeutic HIV Vaccine Industry Chain Analysis
12.2 Therapeutic HIV Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Therapeutic HIV Vaccine Production Mode & Process
12.4 Therapeutic HIV Vaccine Sales and Marketing
12.4.1 Therapeutic HIV Vaccine Sales Channels
12.4.2 Therapeutic HIV Vaccine Distributors
12.5 Therapeutic HIV Vaccine Customers
13 Market Dynamics
13.1 Therapeutic HIV Vaccine Industry Trends
13.2 Therapeutic HIV Vaccine Market Drivers
13.3 Therapeutic HIV Vaccine Market Challenges
13.4 Therapeutic HIV Vaccine Market Restraints
14 Key Findings in The Global Therapeutic HIV Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Therapeutic HIV Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of NRTIs
Table 3. Major Manufacturers of NNRTIs
Table 4. Major Manufacturers of Entry and Fusion Inhibitors
Table 5. Major Manufacturers of Protease Inhibitors
Table 6. Major Manufacturers of Integrase Inhibitors
Table 7. Major Manufacturers of Coreceptor Antagonists
Table 8. Global Therapeutic HIV Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 9. Global Therapeutic HIV Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 10. Global Therapeutic HIV Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Therapeutic HIV Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 12. Global Therapeutic HIV Vaccine Revenue Market Share by Region (2018-2024)
Table 13. Global Therapeutic HIV Vaccine Revenue Market Share by Region (2024-2029)
Table 14. Global Therapeutic HIV Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 15. Global Therapeutic HIV Vaccine Sales by Region (2018-2024) & (K Units)
Table 16. Global Therapeutic HIV Vaccine Sales by Region (2024-2029) & (K Units)
Table 17. Global Therapeutic HIV Vaccine Sales Market Share by Region (2018-2024)
Table 18. Global Therapeutic HIV Vaccine Sales Market Share by Region (2024-2029)
Table 19. Global Therapeutic HIV Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 20. Global Therapeutic HIV Vaccine Sales Share by Manufacturers (2018-2024)
Table 21. Global Therapeutic HIV Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 22. Global Therapeutic HIV Vaccine Revenue Share by Manufacturers (2018-2024)
Table 23. Global Key Players of Therapeutic HIV Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 24. Therapeutic HIV Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 25. Global Therapeutic HIV Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Therapeutic HIV Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic HIV Vaccine as of 2022)
Table 27. Global Key Manufacturers of Therapeutic HIV Vaccine, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Therapeutic HIV Vaccine, Product Offered and Application
Table 29. Global Key Manufacturers of Therapeutic HIV Vaccine, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 32. Global Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 33. Global Therapeutic HIV Vaccine Sales Share by Type (2018-2024)
Table 34. Global Therapeutic HIV Vaccine Sales Share by Type (2024-2029)
Table 35. Global Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 36. Global Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 37. Global Therapeutic HIV Vaccine Revenue Share by Type (2018-2024)
Table 38. Global Therapeutic HIV Vaccine Revenue Share by Type (2024-2029)
Table 39. Therapeutic HIV Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 40. Global Therapeutic HIV Vaccine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 41. Global Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 42. Global Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 43. Global Therapeutic HIV Vaccine Sales Share by Application (2018-2024)
Table 44. Global Therapeutic HIV Vaccine Sales Share by Application (2024-2029)
Table 45. Global Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 46. Global Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 47. Global Therapeutic HIV Vaccine Revenue Share by Application (2018-2024)
Table 48. Global Therapeutic HIV Vaccine Revenue Share by Application (2024-2029)
Table 49. Therapeutic HIV Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 50. Global Therapeutic HIV Vaccine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 51. US & Canada Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 52. US & Canada Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 53. US & Canada Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 54. US & Canada Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 55. US & Canada Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 56. US & Canada Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 57. US & Canada Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 58. US & Canada Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 59. US & Canada Therapeutic HIV Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 60. US & Canada Therapeutic HIV Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 61. US & Canada Therapeutic HIV Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 62. US & Canada Therapeutic HIV Vaccine Sales by Country (2018-2024) & (K Units)
Table 63. US & Canada Therapeutic HIV Vaccine Sales by Country (2024-2029) & (K Units)
Table 64. Europe Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 65. Europe Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 66. Europe Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 68. Europe Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 69. Europe Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 70. Europe Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 72. Europe Therapeutic HIV Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 73. Europe Therapeutic HIV Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Therapeutic HIV Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 75. Europe Therapeutic HIV Vaccine Sales by Country (2018-2024) & (K Units)
Table 76. Europe Therapeutic HIV Vaccine Sales by Country (2024-2029) & (K Units)
Table 77. China Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 78. China Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 79. China Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 80. China Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 81. China Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 82. China Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 83. China Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 84. China Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 85. Asia Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 86. Asia Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 87. Asia Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 88. Asia Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 89. Asia Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 90. Asia Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 91. Asia Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 92. Asia Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 93. Asia Therapeutic HIV Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 94. Asia Therapeutic HIV Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 95. Asia Therapeutic HIV Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 96. Asia Therapeutic HIV Vaccine Sales by Region (2018-2024) & (K Units)
Table 97. Asia Therapeutic HIV Vaccine Sales by Region (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Type (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Type (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Application (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Application (2024-2029) & (K Units)
Table 104. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 107. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 109. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Country (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales by Country (2024-2029) & (K Units)
Table 111. ViiV Healthcare Company Information
Table 112. ViiV Healthcare Description and Major Businesses
Table 113. ViiV Healthcare Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 114. ViiV Healthcare Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. ViiV Healthcare Recent Developments
Table 116. Mylan Company Information
Table 117. Mylan Description and Major Businesses
Table 118. Mylan Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 119. Mylan Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Mylan Recent Developments
Table 121. AbbVie Company Information
Table 122. AbbVie Description and Major Businesses
Table 123. AbbVie Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 124. AbbVie Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. AbbVie Recent Developments
Table 126. Merck & Co., Inc. Company Information
Table 127. Merck & Co., Inc. Description and Major Businesses
Table 128. Merck & Co., Inc. Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 129. Merck & Co., Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Merck & Co., Inc. Recent Developments
Table 131. Bristol-Myers Squibb Company Company Information
Table 132. Bristol-Myers Squibb Company Description and Major Businesses
Table 133. Bristol-Myers Squibb Company Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 134. Bristol-Myers Squibb Company Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Bristol-Myers Squibb Company Recent Developments
Table 136. Boehringer Ingelheim GmbH Company Information
Table 137. Boehringer Ingelheim GmbH Description and Major Businesses
Table 138. Boehringer Ingelheim GmbH Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 139. Boehringer Ingelheim GmbH Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Boehringer Ingelheim GmbH Recent Developments
Table 141. Genentech, Inc. Company Information
Table 142. Genentech, Inc. Description and Major Businesses
Table 143. Genentech, Inc. Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 144. Genentech, Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Genentech, Inc. Recent Developments
Table 146. Cipla, Inc. Company Information
Table 147. Cipla, Inc. Description and Major Businesses
Table 148. Cipla, Inc. Therapeutic HIV Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 149. Cipla, Inc. Therapeutic HIV Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Cipla, Inc. Recent Developments
Table 151. Key Raw Materials Lists
Table 152. Raw Materials Key Suppliers Lists
Table 153. Therapeutic HIV Vaccine Distributors List
Table 154. Therapeutic HIV Vaccine Customers List
Table 155. Therapeutic HIV Vaccine Market Trends
Table 156. Therapeutic HIV Vaccine Market Drivers
Table 157. Therapeutic HIV Vaccine Market Challenges
Table 158. Therapeutic HIV Vaccine Market Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Therapeutic HIV Vaccine Product Picture
Figure 2. Global Therapeutic HIV Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Therapeutic HIV Vaccine Market Share by Type in 2022 & 2029
Figure 4. NRTIs Product Picture
Figure 5. NNRTIs Product Picture
Figure 6. Entry and Fusion Inhibitors Product Picture
Figure 7. Protease Inhibitors Product Picture
Figure 8. Integrase Inhibitors Product Picture
Figure 9. Coreceptor Antagonists Product Picture
Figure 10. Global Therapeutic HIV Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 11. Global Therapeutic HIV Vaccine Market Share by Application in 2022 & 2029
Figure 12. Hospitals
Figure 13. Clinics
Figure 14. Labs
Figure 15. Therapeutic HIV Vaccine Report Years Considered
Figure 16. Global Therapeutic HIV Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Therapeutic HIV Vaccine Revenue 2018-2029 (US$ Million)
Figure 18. Global Therapeutic HIV Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 19. Global Therapeutic HIV Vaccine Revenue Market Share by Region (2018-2029)
Figure 20. Global Therapeutic HIV Vaccine Sales 2018-2029 ((K Units)
Figure 21. Global Therapeutic HIV Vaccine Sales Market Share by Region (2018-2029)
Figure 22. US & Canada Therapeutic HIV Vaccine Sales YoY (2018-2029) & (K Units)
Figure 23. US & Canada Therapeutic HIV Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Europe Therapeutic HIV Vaccine Sales YoY (2018-2029) & (K Units)
Figure 25. Europe Therapeutic HIV Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 26. China Therapeutic HIV Vaccine Sales YoY (2018-2029) & (K Units)
Figure 27. China Therapeutic HIV Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Asia (excluding China) Therapeutic HIV Vaccine Sales YoY (2018-2029) & (K Units)
Figure 29. Asia (excluding China) Therapeutic HIV Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales YoY (2018-2029) & (K Units)
Figure 31. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 32. The Therapeutic HIV Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 33. The Top 5 and 10 Largest Manufacturers of Therapeutic HIV Vaccine in the World: Market Share by Therapeutic HIV Vaccine Revenue in 2022
Figure 34. Global Therapeutic HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 36. Global Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 37. Global Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 38. Global Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 40. US & Canada Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 41. US & Canada Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 42. US & Canada Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 43. US & Canada Therapeutic HIV Vaccine Revenue Share by Country (2018-2029)
Figure 44. US & Canada Therapeutic HIV Vaccine Sales Share by Country (2018-2029)
Figure 45. U.S. Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 46. Canada Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 47. Europe Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 48. Europe Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 49. Europe Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 50. Europe Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 51. Europe Therapeutic HIV Vaccine Revenue Share by Country (2018-2029)
Figure 52. Europe Therapeutic HIV Vaccine Sales Share by Country (2018-2029)
Figure 53. Germany Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 54. France Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 55. U.K. Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 56. Italy Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 57. Russia Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 58. China Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 59. China Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 60. China Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 61. China Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 62. Asia Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 63. Asia Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 64. Asia Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 65. Asia Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 66. Asia Therapeutic HIV Vaccine Revenue Share by Region (2018-2029)
Figure 67. Asia Therapeutic HIV Vaccine Sales Share by Region (2018-2029)
Figure 68. Japan Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 69. South Korea Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 70. China Taiwan Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 71. Southeast Asia Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 72. India Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 73. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue Market Share by Type (2018-2029)
Figure 75. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue Market Share by Application (2018-2029)
Figure 77. Middle East, Africa and Latin America Therapeutic HIV Vaccine Revenue Share by Country (2018-2029)
Figure 78. Middle East, Africa and Latin America Therapeutic HIV Vaccine Sales Share by Country (2018-2029)
Figure 79. Brazil Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 80. Mexico Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 81. Turkey Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 82. Israel Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 83. GCC Countries Therapeutic HIV Vaccine Revenue (2018-2029) & (US$ Million)
Figure 84. Therapeutic HIV Vaccine Value Chain
Figure 85. Therapeutic HIV Vaccine Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries